Navigation Links
Onyx Pharmaceuticals Reports First Quarter 2011 Financial Results
Date:5/4/2011

nd ROW. The replay will be available through May 18, 2011.

About Onyx Pharmaceuticals, Inc.Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer.  The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer.  Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types.  Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a selective proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors.  ONX 0801, an alpha-folate receptor targeted inhibitor of the thymidylate synthase, and ONX 0912, an oral proteasome inhibitor, are currently in Phase 1 testing.  For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Nexavar® (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals, Inc.

This news release contains "forward-looking statements" of Onyx within the meaning of the federal securities laws. These forward-looking statements include, without limitation, statements regarding sales trends and commercial activities, the timing, progress and results of clinical development, and the potential expansion of Onyx's product portfolio. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: Nexavar being our only approved product; we may never receive marketing approval for carfilzom
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , Suisse, October 1, 2014 ... et dans le domaine de l,analyse des données ... aujourd,hui une solution de diagnostic in vitro (IVD) ... analyse complète de la mucoviscidose dans un seul ... de caractériser tous les types de variantes par ...
(Date:9/30/2014)... report analyzes the worldwide markets for Enteral Feeding Devices in ... Nasogastric Tubes, and Others. The report provides separate ... , Europe , Asia-Pacific ... World. Annual estimates and forecasts are provided for the period ... for these markets. The report profiles 38 companies ...
(Date:9/30/2014)... Sept. 30, 2014 MiMedx Group, Inc. (NASDAQ: ... utilizing human amniotic tissue and patent-protected processes to develop ... Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental ... , Ph.D., Chief Scientific Officer, will present at the ... present on Tuesday, October 7, 2014, at 5:00PM Pacific ...
Breaking Medicine Technology:Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 2Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 3Global Enteral Feeding Devices Industry 2Global Enteral Feeding Devices Industry 3Global Enteral Feeding Devices Industry 4Global Enteral Feeding Devices Industry 5Global Enteral Feeding Devices Industry 6Global Enteral Feeding Devices Industry 7Global Enteral Feeding Devices Industry 8Global Enteral Feeding Devices Industry 9Global Enteral Feeding Devices Industry 10Global Enteral Feeding Devices Industry 11Global Enteral Feeding Devices Industry 12Global Enteral Feeding Devices Industry 13Global Enteral Feeding Devices Industry 14Global Enteral Feeding Devices Industry 15Global Enteral Feeding Devices Industry 16Global Enteral Feeding Devices Industry 17Global Enteral Feeding Devices Industry 18Global Enteral Feeding Devices Industry 19MiMedx to Present at the Stem Cell Meeting on the Mesa 2
... Feb. 14, 2011 Thoratec Corporation (Nasdaq: THOR ... to save, support and restore failing hearts, announced today that ... to $100 million of the company,s shares of common stock ... confidence in the long-term strength of the company, as well ...
... 14, 2011 Mesa Laboratories, Inc. (Nasdaq: ... has declared a regular quarterly cash dividend of 12 ... 15, 2011 to shareholders of record at the close ... Laboratories develops, acquires, manufactures and markets electronic instruments and ...
Cached Medicine Technology:Thoratec Corporation Authorizes $100 Million Share Repurchase Program 2Thoratec Corporation Authorizes $100 Million Share Repurchase Program 3
(Date:10/1/2014)... and ATLANTA (PRWEB) October 01, 2014 ... security executive networking and relationship-marketing firm, announced ... Information Security Executive® and Project of the ... top-ranking decision makers representing organizations in financial ... Projects include large-scale technology endeavors that address ...
(Date:10/1/2014)... Beverly Hills licensed Clinical Psychologist and ... 20 years of private practice in her Beverly Hills ... achieve greater joy and fulfillment in their relationships. Dr. ... and suggestions for anyone who suspects they are in ... it or not, it’s not always easy to know ...
(Date:10/1/2014)... 01, 2014 NoteSwift Inc., announced today ... 10.0, 12.1 and 13.0. NoteSwift is the bridge between ... to navigate and document clinical information at the point ... creating a patient note by more than half – ... major pain points providers state impedes EHR use according ...
(Date:10/1/2014)... Ethiopia, at the occasion of the Leishmaniasis East ... African and international leishmaniasis experts, results of a ... monitoring plan, carried out by MSF, DNDi, ... Ethiopia, were presented to key decision makers in ... kala-azar with the combination of Sodium Stibogluconate and ...
(Date:10/1/2014)... Dr. Saj Jivraj, one of the ... traveling to Chennai, India, tomorrow to speak at the ... 3. , Dr. Jivraj is founder of the Anacapa ... and one of the world’s foremost prosthodontists, meaning he ... is speaking to the Indian Society of Oral Implantologists ...
Breaking Medicine News(10 mins):Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 5Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 6Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 7Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3Health News:NoteSwift Joins Allscripts Developer Program 2Health News:NoteSwift Joins Allscripts Developer Program 3Health News:Results of large-scale roll out of combination treatment for kala-azar in Eastern Africa 2Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 2Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 3Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 4Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 5
... 12 DARA,BioSciences, Inc. ("DARA") and Point Therapeutics, Inc. ... effective as,of the close of business on February 12, ... the respective stockholders,of DARA and Point. Immediately prior to ... split of its common stock pursuant to which,each 40 ...
... Ohio, Feb. 12 AtriCure, Inc.,(Nasdaq: ATRC ), ... surgical,ablation products, announced today that David J. Drachman, President ... Roth Capital,Partners 20th Annual OC Growth Stock Conference at ... Wednesday, February 20th at 2:00 p.m.,PT., A live ...
... tumors tend to survive longer and are more responsive ... to a study published online February 12 in the ... , Human papillomavirus has been shown to be involved ... particularly cancers of the upper throat, or oropharynx. Retrospective ...
... Deaths More Common Among Breast Cancer Survivors ... at greater risk of death from non-cancer causes ... cancer treatments improve, patients are surviving longer, and ... cancer. Judith-Anne Chapman, Ph.D., and colleagues with the ...
... 2008 -- In a study to examine the impact of ... report over one month, researchers at Columbia University Mailman School ... was a more accurate predictor of physically and mentally unhealthy ... to lose weight was more predictive of unhealthy days among ...
... to treatment than those with HPV-negative tumors , , TUESDAY, ... patients whose tumors test positive for human papillomavirus (HPV) ... than those who test negative, a new study says. ... be responsible for most cervical cancers, has recently been ...
Cached Medicine News:Health News:DARA BioSciences, Inc. and Point Therapeutics, Inc. Announce Consummation of Merger 2Health News:AtriCure to Present at Roth Capital Partners 20th Annual OC Conference 2Health News:Other highlights in the Feb. 12 JNCI 2Health News:Other highlights in the Feb. 12 JNCI 3Health News:Other highlights in the Feb. 12 JNCI 4Health News:Body image is stronger predictor of health than obesity, says Mailman School of PH study 2
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Low-profile, hand-held instrument....
Low-profile, hand-held instrument....
Developed in conjunction with Pierce E. Scranton, Jr., M.D., the Seattle Small Joint Arthroscopy Set offers meticulously designed instrumentation for elbow, foot, and ankle surgeries....
Medicine Products: